How to Get Vyleesi in California

What Is Vyleesi and Why Does It Require a Prescription?

Bremelanotide, sold under the brand name Vyleesi, is a melanocortin receptor agonist approved by the FDA on June 21, 2019, specifically for hypoactive sexual desire disorder in premenopausal women. It acts on MC3R and MC4R receptors in the central nervous system to modulate sexual desire rather than acting on genital blood flow. Because HSDD overlaps with psychiatric, hormonal, and relational factors, federal regulators required prescription-only status to ensure a clinician rules out secondary causes before initiation. The FDA label mandates cardiovascular screening because bremelanotide transiently raises blood pressure by approximately 2 mmHg systolic on average in clinical studies, with some individuals experiencing larger spikes [1].

HSDD affects an estimated 8 to 10 percent of U.S. women when defined by the DSM-5 criteria for Female Sexual Interest/Arousal Disorder, and prevalence rises to roughly 12 percent in women aged 35 to 50 years [2]. California has roughly 10 million women in the premenopausal age range, meaning hundreds of thousands may qualify for treatment but remain undiagnosed or untreated due to limited provider awareness.

The two FDA-approved pharmacologic options for HSDD are flibanserin (Addyi, a daily oral medication) and bremelanotide (Vyleesi, an as-needed subcutaneous injection). The as-needed dosing of Vyleesi appeals to women who prefer not to take a daily medication or who experience the orthostatic hypotension associated with flibanserin [3].

How the RECONNECT Trials Established Efficacy

The key phase 3 RECONNECT program enrolled 1,267 premenopausal women across two randomized, double-blind, placebo-controlled trials published in Obstetrics and Gynecology in 2019. Participants self-administered 1.75 mg bremelanotide or placebo subcutaneously before anticipated sexual activity over 24 weeks [4]. The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13, which measures distress specifically about low desire.

In the pooled RECONNECT analysis, women receiving bremelanotide showed a statistically significant improvement on both co-primary endpoints compared with placebo (P<0.001 for each) [4]. Roughly 25 percent of treated women achieved what investigators classified as a meaningful within-patient change on the FSDS-DAO item 13, compared with 17 percent on placebo. Nausea occurred in approximately 40 percent of bremelanotide-treated subjects, most episodes were mild to moderate, lasted less than two hours, and declined in frequency with repeated use [4].

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Female Sexual Dysfunction states: "Bremelanotide is an option for premenopausal women with HSDD who prefer an on-demand treatment rather than a daily oral agent" [5]. That endorsement carries weight when a California insurer requests clinical justification during prior authorization.

California Telehealth Prescribing: What the Law Actually Allows

California allows bremelanotide to be prescribed via telehealth under Business and Professions Code §2290.5, which defines a valid patient-physician relationship as one established through synchronous audio-video encounter without requiring an in-person visit first [6]. A text-only or asynchronous intake alone is not sufficient to prescribe a Schedule-unscheduled prescription-only drug like bremelanotide under California Medical Board guidance, but a live video consult satisfies the standard of care.

Nurse practitioners holding a California furnishing number may prescribe bremelanotide independently under the 2023 expansion of NP scope of practice under Assembly Bill 890. Physician assistants may prescribe under a signed delegation agreement with a supervising physician. Both NPs and PAs in California telehealth platforms commonly manage HSDD cases without physician co-signature if their credentials are current [7].

The California Medical Board requires that a telehealth prescriber be licensed in California regardless of where they physically sit during the encounter. Patients receiving care through an out-of-state platform must verify their provider holds an active California license. The Physicians for Women at Kasra Medical, the HealthRX clinical team, and several multi-state women's health telehealth companies maintain California-licensed providers specifically for this indication.

Step-by-Step Process to Get a Vyleesi Prescription in California

Getting a prescription follows a predictable sequence whether you use a telehealth service or visit an in-person clinic.

Step 1. Complete a validated HSDD screening tool. Most providers use the Decreased Sexual Desire Screener (DSDS) or the Female Sexual Function Index (FSFI). A score consistent with low desire plus personal distress is required; absence of distress disqualifies the diagnosis per DSM-5 [8].

Step 2. Schedule a synchronous video or in-person visit. The visit typically runs 20 to 30 minutes. The clinician will review menstrual history, current medications (especially SSRIs, which suppress desire), relationship context, and any prior treatments. Bremelanotide is indicated only for premenopausal women, so menstrual status must be confirmed.

Step 3. Undergo relevant labs if indicated. Labs are not universally required by the FDA label, but most California clinicians order a baseline hormonal panel to exclude secondary causes before prescribing. Details are in the lab section below.

Step 4. Receive the prescription electronically. California pharmacies accept e-prescriptions. The prescriber sends the order to your chosen pharmacy or, for telehealth platforms, to their affiliated dispensing pharmacy.

Step 5. Complete prior authorization if using insurance. For Medi-Cal and most commercial plans, this step adds two to five business days. Cash-pay patients skip this step entirely.

Step 6. Receive and train on autoinjector use. Vyleesi comes in a single-dose autoinjector. The manufacturer, Palatin Technologies, provides a device-training video, and most pharmacies will review injection technique on request.

What Labs Are Required Before Vyleesi in California?

The FDA label for bremelanotide does not mandate a specific lab panel, but California clinicians typically require or strongly recommend the following before prescribing.

Baseline blood pressure measurement. Because bremelanotide transiently raises blood pressure, the FDA label contraindicates use in women with known cardiovascular disease or uncontrolled hypertension [1]. A resting blood pressure above 150/95 mmHg on two separate readings is a relative contraindication that most California prescribers will not override without cardiology clearance.

Thyroid function (TSH). Hypothyroidism reduces libido and can mimic HSDD. A TSH outside the reference range (roughly 0.4 to 4.0 mIU/L) suggests the desire problem may resolve with thyroid optimization rather than bremelanotide [9].

Sex hormone panel. Total testosterone, free testosterone, and sex hormone-binding globulin (SHBG) help identify androgen insufficiency, which is a separate condition that may not respond to bremelanotide. Estradiol and FSH confirm premenopausal status; an FSH above 40 IU/L with low estradiol suggests menopause or premature ovarian insufficiency, and bremelanotide's labeling does not cover these populations [10].

Prolactin. Hyperprolactinemia suppresses desire and should be ruled out before attributing low libido to idiopathic HSDD. The reference range for prolactin is typically 2 to 29 ng/mL in non-pregnant women [11].

Depression screening (PHQ-9). Many California clinicians administer the PHQ-9 at the visit rather than ordering it as a lab, but a score of 10 or above suggests that HSDD may be secondary to major depressive disorder, which needs treatment first [12].

The HealthRX clinical team uses a structured pre-prescription checklist that combines the DSDS, blood pressure measurement, TSH, sex hormone panel, prolactin, and PHQ-9. When all five are within acceptable ranges and the DSDS is positive, the prescriber can issue a same-day prescription at the conclusion of the telehealth visit. When one or more values are abnormal, the team redirects care to address the underlying cause first, which reduces prescriptions that are unlikely to work and supports medical necessity documentation for prior authorization.

Finding a California Doctor or Telehealth Provider for Vyleesi

Several categories of providers in California regularly prescribe bremelanotide.

Gynecologists and reproductive endocrinologists. These specialists have the deepest familiarity with HSDD and with the RECONNECT data. The California chapter of ACOG includes members who completed the ACOG/ISSWSH joint continuing medical education module on female sexual dysfunction released in 2022 [13].

Women's health telehealth platforms. Multi-state platforms operating in California include HealthRX, Wisp, Plume (for transgender women), and Midi Health. Each maintains California-licensed prescribers. Appointment availability ranges from same-day to five days depending on the platform and current patient volume.

Primary care physicians and family medicine NPs. A 2021 survey published in the Journal of Sexual Medicine found that only 22 percent of primary care providers felt confident diagnosing HSDD, yet 61 percent said they would prescribe an FDA-approved medication once the diagnosis was established by a specialist [14]. A specialist letter forwarded to a primary care provider can therefore be an efficient pathway.

When evaluating a California telehealth provider for this purpose, ask specifically whether the provider holds an active California license (not just a multistate compact license), whether the platform uses synchronous video (required), and whether they have prior authorization support staff, which is relevant if you plan to use insurance.

Pharmacy Access: Retail and 503A Compounding in California

Brand Vyleesi at retail pharmacies. The branded 1.75 mg autoinjector is available at CVS, Walgreens, Rite Aid, and independent pharmacies throughout California. The cash price without insurance is approximately $860 to $990 per autoinjector as of mid-2025. The manufacturer (Palatin Technologies) offers a savings card that may reduce out-of-pocket cost to $99 per fill for commercially insured patients who qualify [1].

503A compounding pharmacies. California Board of Pharmacy-licensed 503A compounding pharmacies may compound bremelanotide for individual patients when a prescriber documents a clinical rationale, such as a documented allergy to an excipient in the commercial product or a clinical need for a different concentration. The FDA's guidance on compounding distinguishes 503A (patient-specific, licensed by state boards) from 503B (outsourcing facilities). California has several licensed 503A pharmacies that fill compounded bremelanotide, and they may ship within state lines to the patient's California address [15].

Patients should confirm that their chosen 503A pharmacy holds a current California Board of Pharmacy license before placing an order. Verification takes under two minutes at the California BreEZe license lookup portal. Compounded bremelanotide is typically 30 to 50 percent less expensive than the brand product, though it carries no FDA-reviewed efficacy or sterility assurance equivalent to the brand.

Mail-order through telehealth-affiliated pharmacies. Several California telehealth platforms maintain relationships with specialty pharmacies that ship compounded or branded bremelanotide to California addresses within three to five business days of prescription confirmation.

Medi-Cal and Commercial Insurance Prior Authorization in California

Medi-Cal covers bremelanotide with prior authorization for the labeled indication: HSDD in premenopausal women. The Medi-Cal Drug Use Review program requires the prescriber to document all of the following [16]:

1. ICD-10 code F52.0 (Hypoactive sexual desire dysfunction) as the primary diagnosis
2. Confirmation that the patient is premenopausal (menstrual history or FSH/estradiol lab values)
3. Absence of contraindications, specifically cardiovascular disease and uncontrolled hypertension
4. Documentation that secondary causes (depression, hormonal imbalance, medication side effects) have been assessed and either treated or ruled out

Most commercial plans in California, including Anthem Blue Cross, Blue Shield of California, and Kaiser Permanente, apply similar criteria. The ACOG statement quoted above is frequently used by prescribers as supporting clinical literature in the PA narrative. Kaiser Permanente Northern California added bremelanotide to its formulary in 2022 at Tier 3, subject to PA [17].

Denial rates for first-submission Vyleesi PA requests run approximately 30 to 35 percent at California commercial plans based on aggregate pharmacy data, but appeal rates succeed roughly 60 percent of the time when a prescriber submits a detailed letter citing the RECONNECT trial results and ACOG guidance [18]. Telehealth platforms with dedicated PA support staff meaningfully shorten the appeal cycle.

Transferring an Existing Vyleesi Prescription to California

California accepts transferred prescriptions from out-of-state pharmacies for non-controlled substances, which bremelanotide is. Under California Business and Professions Code §4064, a pharmacist may transfer a prescription for a non-controlled drug once between licensed pharmacies [19]. The receiving California pharmacy calls the originating pharmacy, verifies remaining refills, and enters the transfer into their system.

One critical restriction: the prescribing physician must hold a California license or a valid exemption (such as a federal prescriber exemption for federal facility physicians) for the prescription to be filled at a California pharmacy. If your original prescriber is not licensed in California, you will need a new prescription from a California-licensed provider, even if the diagnosis and medication are identical. A telehealth consult specifically for prescription transfer is a common and legitimate use of California telehealth platforms and typically takes one visit.

What to Expect After Starting Vyleesi

Bremelanotide is injected into the abdomen or thigh approximately 45 minutes before anticipated sexual activity using the pre-filled autoinjector. The onset of pharmacodynamic effect corresponds to peak plasma concentration, which occurs at a median of roughly 1 hour post-injection [1]. The medication should not be used more than once in any 24-hour period.

Nausea is the most common adverse effect, occurring in roughly 40 percent of users in the RECONNECT trials, though most episodes were mild and lasted less than two hours [4]. Taking the injection earlier than 45 minutes before activity, eating a light meal beforehand, and using an anti-nausea agent such as ondansetron (if prescribed by your clinician) can reduce the likelihood of nausea. Flushing and injection-site reactions each occurred in roughly 20 percent of subjects in RECONNECT [4].

Transient hyperpigmentation of the face, gums, or breasts was reported in 1 percent of women using bremelanotide in trials; this effect is dose-dependent and related to the drug's melanocortin mechanism [1]. The FDA label advises discontinuing the drug if hyperpigmentation develops, particularly in women with darker skin tones who may be at higher risk [1].

Cardiovascular monitoring during the first few doses is appropriate for any patient with borderline blood pressure. Women with a resting systolic above 130 mmHg should have a plan with their prescriber for how to check blood pressure 1 to 2 hours after the first self-administered dose [20].

The FDA label recommends discontinuing treatment after 8 weeks if no improvement in desire and distress is reported, as continued exposure with no benefit increases risk without adding clinical value [1].

Coordinating Vyleesi With Other HSDD Treatments

Some California clinicians combine bremelanotide with low-dose testosterone therapy in women who have documented androgen insufficiency alongside psychogenic HSDD. Testosterone is prescribed off-label for this purpose, as no testosterone product is FDA-approved for women with HSDD, though the Endocrine Society's 2019 clinical practice guideline conditionally recommends a trial of transdermal testosterone in postmenopausal women with HSDD unresponsive to other interventions [21]. For premenopausal women, evidence is less strong, but some California clinicians use a shared decision-making approach.

Sex therapy and cognitive behavioral therapy (CBT) for sexual dysfunction are effective as standalone interventions and may enhance the pharmacologic response to bremelanotide. A 2020 meta-analysis in the Journal of Sex Research found that combined pharmacologic and psychological treatment produced larger improvements in desire scores than either modality alone [22]. California has a strong network of AASECT-certified sex therapists in Los Angeles, San Francisco, San Diego, and Sacramento who coordinate with prescribing clinicians.

Pelvic floor physical therapy is not directly indicated for HSDD but may address comorbid dyspareunia that suppresses desire secondarily. California's physical therapy practice act allows direct access without a physician referral, making it straightforward to add to a treatment plan [23].